February 2005 produced a consensus statement for the care of these newborns.
Methods: Linked population birth, death and neonatal intensive care unit (NICU) data were obtained for all births in New South Wales, Australia from 2000 to 2011 and divided into two epochs (I:2000 (I: -2005 (I: , II:2006 (I: -2011 . To determine the effect of the Consensus differences in resuscitation practices were used as a primary outcome to adjust for NICU admission and hospital survival rates between the two epochs.
Results Iron deficiency anaemia (IDA) affects up to 20% of pregnancies globally. Despite the prevalence and association of iron deficiency (ID) with significant maternal and fetal sequelae, treatment remains suboptimal and the impact of treatment on pregnancy outcomes unclear.
Methods: A prospective quantitative survey-based study of perinatal clinicians and pregnant women attending antenatal clinics at two Sydney metropolitan hospitals, regarding a potential first-line oral versus intravenous (IV) iron randomised controlled trial (RCT) in pregnancy.
Results: Amongst 74 clinicians (36% physicians, 31% midwives, 22% obstetricians, 11% others), 80% theoretically supported an IDA RCT and 61% an ID without anaemia RCT. Haematological, transfusion and clinical outcome categories were most important to clinicians. Of 116 patients, 62% previously had ID and 72% currently did. Associated adverse effects caused 20% of patients to stop oral iron before course completion. Twothirds of women were "maybe" or more likely to participate in an IDA RCT. Bad tablet experience (p=0.004) and time taken to correct IDA (p=0.013) were motivators for participation and bad IV experience (p=0.031), fear of IV injections (p=0.001), and randomisation (p=0.001) were barriers. Baby safety, speed of blood count improvement and maternal side effects were the most important outcomes to women.
Conclusions: An RCT of intravenous versus oral iron as firstline therapies for IDA in later pregnancy may be feasible, however not ID without anaemia. Trial design and outcomes studied should address the clinician and patient priorities raised by this study. Background: Antenatal glucocorticoids (GC) alter circulating levels of neurotrophins (NT), proteins critical for neural growth, survival and differentiation. Emerging data suggests GCs have differing effects in preterms with fetal growth restriction (FGR) compared to those normally grown, including effects on the developing brain. We investigated the effect of GC exposure on umbilical cord blood NTs in normally grown and growth restricted very preterm infants.
INFLUENCE OF TIMING OF ANTENATAL GLUCOCORTICOID EXPOSURE ON UMBILICAL CORD BLOOD NEUROTROPHINS CONCENTRATION IN APPROPRIATELY GROWN AND GROWTH RESTRICTED VERY PRETERM INFANTS
Methods: Cord blood NT-3, NT-4, and brain derived neurotrophic factor (BDNF) were measured by ELISA in appropriately grown (n=161) and FGR infants (n=74) born <29 week's gestation. Steroid exposure was defined as <24 hours, 24 hours to 7 days and >7 days prior to delivery.
Results: The proportion of infants in each steroid exposure group was similar for both normal and FGR groups. NT-3 did not differ by steroid exposure or birthweight group. A main effect for steroid exposure was seen for NT-4 with delivery 24 hours to 7 days after GC exposure associated with higher concentrations (p<0.01). An interaction effect of steroid exposure and birthweight was present for BDNF (p<0.05) with concentrations lower if growth restricted (p=0.01), and declining with increasing time from steroid exposure in the FGR group alone (p<0.01).
Conclusions: Timing of GC exposure prior to delivery alters cord blood NTs with BDNF lower in FGR infants and reduced further following GC exposure. With FGR associated with placental insufficiency, these findings may represent specific steroid mediated effects on placental NT production compounding preexisting dysfunction which may contribute to adverse neurodevelopmental outcome. Preterm birth adversely impacts kidney development, function, and may lead to renal disease; the incidence of renal disease in Australia is disproportionately high amongst Indigenous populations. The aim of this study was to determine the impact of preterm birth, and related factors, on renal function in Indigenous and non-Indigenous infants.
POTENTIAL ANTENATAL AND POSTNATAL DETERMINANTS OF IMPAIRED RENAL FUNCTION IN INDIGENOUS PRETERM INFANTS
Methods: Urine samples were obtained from Indigenous (n=67) and non-Indigenous (n=54) infants (born 24-41 weeks gestation) on days 4-8, 15, 22 and 29 to assess creatinine clearance, fractional excretion of sodium (FENa), NGAL (injury marker), albumin and β-2 microglobulin levels. Data were assessed using multilevel mixed-effects linear regression, adjusting for gestational age, postnatal age, sex, and birthweight z-score.
Results: Throughout the first month of life, Indigenous infants exhibited significantly increased urine albumin, β-2 microglobulin and FENa in comparison to non-Indigenous infants. Maternal cigarette smoking was significantly associated with increased NGAL excretion; this increase was significantly greater in Indigenous compared to non-Indigenous infants (mean difference β 1.41 [1.00-1.99], p=0.048). Postnatal antibiotic treatment with benzylpenicillin and gentamicin was also associated with significantly increased NGAL excretion in Indigenous, but not non-Indigenous, infants (mean difference β 10. 46 [3.04-35 .99], p<0.0001). Vancomycin and cefotaxime antibiotics were each associated with a significant reduction in creatinine clearance, and an increase in FENa; Indigenous infants were affected to a significantly greater extent than non-Indigenous infants.
Conclusions: Maternal smoking and postnatal antibiotic administration appear to adversely impact renal function in preterm neonates, with Indigenous infants more vulnerable. Edition (BSID) and/or the Ages and Stages Questionnaire (ASQ) on an intention to treat basis. Children were compared for initial FiO 2 0.21 or 1.0, 5 min SpO 2 (</≥80%) and gestation (</≥28 weeks). Co-primary outcomes were: 1) developmental delay and 2) death and/or delayed.
PRETERM INFANT OUTCOMES AFTER
Results: Follow-up data were available for 240/290 (83%) children. Developmental assessments were performed on 202/240 (84%) children. There was no difference in the risk of disability/death or survival without disability with FiO 2 0.21 or 1.0 (OR 0.61 95% CI: 0.35-1.06). Children with 5 minute SpO 2 ≥80% were less likely to be dead/disabled (OR 0.44, 95% CI: 0.25-0.77, p=0.004) or alive without disability (0.51, 0.27-0.98, p=0.03). Composite BSID cognitive scores were higher in children ≥28 weeks gestation with 5 minute SpO 2 ≥80% (v <80%, mean:100.8 v 95.2, p=0.02).
Conclusions: Initiating preterm infant resuscitation with either FiO 2 0.21 or 1.0 does not make a difference to the composite of death or disability but children with 5 minute SpO 2 <80% have poorer outcomes. The implications of fiO 2 adjustment during resuscitation should be evaluated in sufficiently large randomised controlled trials.
